| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1968903 | Clinical Biochemistry | 2014 | 7 Pages |
•Cancer biorepository is a key component for personalized medicine advancement.•Quality control is an essential component of biorepository development and operations.•Clinical biorepository requires the highest standards for operations.•Biorepository development needs institutional cooperation and support.•Pathology expertise is necessary for biorepository development and operations.
High quality human biospecimens, such as tissue, blood, cell derivatives, and associated patient clinical information, are key elements of a scientific infrastructure that supports discovery and identification of molecular biomarkers and diagnostic agents. The goal of most biorepositories is to collect, process, store, and distribute human biospecimen for use in basic, translational and clinical research. A biorepository serving as the central hub provides investigators with an invaluable resource with appropriately examined and characterized biospecimens with associated patient clinical information. Expertise in standardization, quality control, and information technology, and awareness of cutting edge research developments are generally required for biorepository development and management. The availability of low cost whole genome profiles of individual tumors has opened up new possibilities for personalized medicine to deliver the most appropriate treatments to individual patients with minimal toxicity. A biorepository in support of personalized medicine thus requires the highest standards of operation and adequate funding, training and certification. This review provides an overview of the development of an institutional cancer biorepository for clinical research and personalized medicine advancement.
